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Use of domperidone and risk of ventricular arrhythmia in the postpartum period: getting to the 
heart of the matter 
To the editor  
We read with interest the study by Smolina et al investigating domperidone prescription for lactation 
stimulation and hospitalisation for ventricular arrhythmia.1 There is significant controversy 
surrounding the use of domperidone for increasing breast milk supply, relating to both its perceived 
efficacy and safety, which has led to it becoming the subject of numerous reviews and debates.2,3 In 
light of such controversies, it is important to have transparent and clear reporting of research findings, 
given their role in guiding subsequent clinical practice. This goes for any reporting of benefits or risks 
associated with the use of domperidone. We believe that the conclusion reached by Smolina et al. that 
they “found a possible association between exposure to domperidone and hospitalisation for 
ventricular arrhythmia among a cohort of women who have recently given birth”,1 does not accurately 
represent the entirety of the data upon which the conclusion is based due to the following three issues.  
The first issue relates to reporting effect measure modification of the association between 
domperidone and ventricular arrhythmia by previous history of ventricular arrhythmia. The authors 
comment on the lack of ability to investigate an interaction between domperidone exposure and 
history ventricular arrhythmia due to the fact that all 6 women exposed to domperidone and 
hospitalised for ventricular arrhythmia also had a history of ventricular arrhythmia. Visual inspection 
of the data (Table 1) points to effect measure modification by history of ventricular arrhythmia. In the 
stratum of women who have no history of ventricular arrhythmia (n=318,516), there were no 
ventricular arrhythmia events among the 45,163 women prescribed domperidone, and all ventricular 
arrhythmia events arose in women who were not prescribed domperidone.  Different results are 
obtained by looking across stratum of ventricular arrhythmia history; negligible risk among women 
with no ventricular arrhythmia history and some increased level of risk among history of ventricular 
arrhythmia but there are too few cases to estimate with accuracy.  Drawing conclusions from the 
pooled data hides the fact that the burden of risk is in the group of women with ventricular arrhythmia 




history.  A more balanced interpretation might be that use of domperidone is associated with an 
increased risk of ventricular arrhythmia among women with a previous history of ventricular 
arrhythmia, but not among those with no ventricular arrhythmia history.  The conclusion reached by 
the study authors does not reflect this differential risk and has potential to reduce domperidone 
prescriptions and lactation success for all women, irrespective of their history. Therefore, we ask that 
the adjusted stratum-specific hazard ratios be presented separately according to ventricular arrhythmia 
history.  
The second issue relates to the potential for significant residual confounding of the association 
between domperidone exposure and hospitalisation for ventricular arrhythmia in women with a 
previous history of ventricular arrhythmia. Confounding appears to be a significant factor, as 
evidenced by the change in the overall risk estimate when accounting for maternal body mass index, 
for which complete data was notably absent. The approach undertaken for confounder selection is not 
entirely clear, with the inclusion of only some cardiovascular risk factors such as smoking as 
confounders while other factors such as thyroid dysfunction, diabetes and hypertension (whether pre-
existing or pregnancy induced) are omitted. Further, preterm birth or neonatal hospitalisation are 
potential confounders, as both of these are strongly associated with domperidone use4-6 and can lead 
to significant physical and emotional stress during the post-partum period, the latter of which is a 
noted factor influencing rhythm disorders among some women.7 While it is appreciated that the 
number of covariates was limited to avoid over-fitting the model, the authors could consider use of 
alternative propensity score methodology which has demonstrated robustness in the setting of large 
numbers of potential confounders relative to uncommon outcomes.8  
The third issue relates to the manner in which domperidone exposure was classified and included in 
the analyses. It is noted that of the six women exposed to domperidone who were hospitalised for 
ventricular arrhythmia, only four had a current domperidone prescription at the time of 
hospitalisation. This aspect requires clarification as it is unclear why women would continue to be 
treated as exposed until 30 days after the day that the last postpartum domperidone prescription would 




have run out, when based on a biological half-life of 7.5 hours9, domperidone would take less than 48 
hours to be cleared from the body after the final dose has been taken.  
In light of the findings of the study by Smolina et al., we feel that a more appropriate summary for 
clinicians and lactating mothers considering the use of domperidone would be: Among mothers with 
no previous history of ventricular arrhythmia, no increased risk was observed between the use of 
domperidone and risk of subsequent ventricular arrhythmia. In contrast, in mothers with a previous 
history of ventricular arrhythmia, the use of domperidone may be associated with a small absolute 
increase in the risk (1.7 to 2.3 fold based on adjusted hazard ratio) of subsequent ventricular 
arrhythmia (an absolute increase from 68 cases per 10,000 women to 115-157 cases per 10,000 
women). Therefore, use of domperidone in women with a previous history of ventricular arrhythmia 
should be cautioned and only undertaken under careful supervision. Overall, domperidone should 
only be considered after a careful evaluation of the anticipated benefits and risks for each individual 
mother-child pair and should never be seen as a replacement for non-pharmacological strategies for 
increasing breast milk supply. 
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Table 1. Numbers of women exposed and not exposed to domperidone in the 
postpartum period and subsequent development of ventricular arrhythmia 
Overall Cohort 
 VA No VA Total 
Domperidone 6 45,512 45,518 
No Domperidone 15 274,818 274,833 
Stratified According to History of Ventricular Arrythmia (VA) 
Previous History of VA 
 VA No VA Total 
Domperidone 6 349 355 
No Domperidone 10 1,470 1,480 
No History of VA 
 VA No VA Total 
Domperidone 0 45,163 45,163 
No Domperidone 5 273,348 273,353 
 
 
